ArticleJNCI cancer spectrum2026
Homologous recombination repair germline variants and subsequent neoplasm risk among childhood cancer survivors.
Article in JNCI cancer spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Childhood cancer radiation therapy (RT) increases subsequent neoplasm risk. Radiation dose may modulate DNA damage responses, but the small sample sizes of prior human studies of homologous recombination repair hampered dose-specific investigations. We pooled data for 12 180 survivors (8339 from the Childhood Cancer Survivor Study and 3841 from the St Jude Lifetime Cohort) to estimate associations between deleterious homologous recombination repair variants and RT-related subsequent neoplasms (most commonly breast cancer, meningioma, thyroid cancer, and sarcoma) using conditional logistic regression with matched controls. In all, 1253 (10.3%) survivors were homologous recombination repair variant carriers, and 1301 (10.7%) developed at least 1 RT-related subsequent neoplasms. Variants increased the risk of out-of-field RT-related subsequent neoplasms (cases, 40/190 [21.1%]; control individuals, 9.7%; odds ratio [OR] = 2.5, 95% confidence interval [CI] = 1.7 to 3.6; P = 4.80 ×10-6), with consistent results across cohorts (Childhood Cancer Survivor Study, OR = 2.5, 95% CI = 1.6 to 3.7, P = 3.77 ×10-5; St Jude Lifetime Cohort, OR = 2.5, 95% CI = 1.0 to 6.4, P = 3.07 ×10-2). No association was observed for in-field or near-field subsequent neoplasms or individuals not undergoing RT. Findings emphasize homologous recombination repair variant-conferred susceptibility to RT-related subsequent neoplasms and dose-dependent DNA damage repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.